Davidson Kempner Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Davidson Kempner Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-222,482	Closed	-$590K	–	242
2025 Q3	$590K	Hold	222,482	–	–	0.01%	185
2025 Q2	$219K	Hold	222,482	–	–	﹤0.01%	159
2025 Q1	$320K	Hold	222,482	–	–	﹤0.01%	162
2024 Q4	$489K	Hold	222,482	–	–	0.01%	156
2024 Q3	$367K	Hold	222,482	–	–	0.01%	144
2024 Q2	$489K	Hold	222,482	–	–	0.01%	178
2024 Q1	$594K	Hold	222,482	–	–	0.01%	173
2023 Q4	$663K	Hold	222,482	–	–	0.01%	149
2023 Q3	$219K	Hold	222,482	–	–	﹤0.01%	163
2023 Q2	$309K	Hold	222,482	–	–	0.01%	175
2023 Q1	$354K	Buy	+222,482	New	+$1.15M	0.01%	220

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Davidson Kempner Capital Management's ESPR Position: Q4 2025 in Review

Davidson Kempner Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 222,482 shares — an estimated $590K sold.

Davidson Kempner Capital Management first reported a position in ESPR in Q1 2023 and held it in 11 quarters. The position peaked at $663K in Q4 2023. 201 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

Davidson Kempner Capital Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
Davidson Kempner Capital Management sold 222,482 Esperion Therapeutics shares in Q4 2025, an estimated $590K.
Davidson Kempner Capital Management first reported a position in Esperion Therapeutics in Q1 2023 and held it in 11 quarters.
Davidson Kempner Capital Management's Esperion Therapeutics position peaked at $663K in Q4 2023.
201 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.